The end of the year is coming and 2015 is fast approaching. And as we all start to think about what the New Year will mean for you, what will 2015 hold for pharmaceuticals?
The Federal Drug Administration already has several decisions on the calendar. According to RTT News,The FDA is so far set to rule on seven proposed medications.
January
- RYTARY: for the treatment of idiopathic Parkinson’s disease
- Triferic: for treating iron deficiency in chronic kidney disease patients on hemodialysis
- Triferic: for the treatment of iron replacement and maintenance of hemoglobin in hemodialysis patients
February
- Lucentis: for the treatment of diabetic retinopathy
- Levosert: a hormonal intrauterine contraceptive for use by women to prevent pregnancy.
- XIFAXAN: for the treatment of irritable bowel syndrome with diarrhea or IBS-D
March
- EXPAREL: for use in femoral nerve block for total knee arthroplasty
To read more about the FDA’s 2015 calendar click here.
To stay abreast of all new available medications as well as other points of interest in the constantly-changing world of pharmaceuticals, a reputable partner like Northwind is a great advantage.
Contact us today to see how our solutions can lead to a better 2015.
